Cytokinetics
(NASDAQ:CYTK)
$63.68
-0.34[-0.53%]
Last update: 9:30AM Get Real Time Here
Q1 2024 Earnings were released on Wed May 8th, after the market close
The most recent conference call was at 16:30 PM, 2 days ago Click to view past webcast
OverviewNewsEarningsGuidanceDividendsAnalyst RatingsInsider TradesShort Interest

Cytokinetics Stock (NASDAQ:CYTK), Quotes and News Summary

Cytokinetics Stock (NASDAQ: CYTK) stock price, news, charts, stock research, profile.

Open$63.630
Close-
Volume / Avg.660.381K / 1.928M
Day Range61.250 - 64.610
52 Wk Range25.980 - 110.250
Market Cap$6.659B
P/E Ratio-
Dividend Yield-
ExchangeNASDAQ
RSI
40
Short Interest
21.97%
Days to Cover14.36

Recent News

Omega Therapeutics, Inc. Reports Q1 Loss, Tops Revenue Estimates
Omega Therapeutics, Inc. (NASDAQ: OMGA) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to loss of $0.50 per share a year ago. These figures are adjusted for non-recurring items.
Zacks
Banco Santander, Lloyds Banking And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were lower this morning, with the Dow futures falling over 100 points on Monday. Shares of Banco Santander, S.A. (NYSE: SAN) shares fell sharply during today’s pre-market trading.
Avi Kapoor
Cytokinetics' Heart Drug Is A Multi-Billion Dollar Opportunity By 2032 Despite Novartis Setback: Analyst
Novartis halts pursuit of Cytokinetics acquisition, impacting promising heart drug. Analysts estimate $3.6 billion sales for Cytokinetics' cardiomyopathy drug by 2032. Still lead drug aficamten viewed as a distinctive therapy for Hypertrophic Cardiomyopathy.
Vandana Singh
-%

Financials

Quarterly
Annual
Name
Revenue
Change
Gross
Change
EBITDA
Change
EBIT
Change
Earnings
Change
Analyst Trend
2
Feb
3
Mar
2
Apr
4
May
Buy
Hold
Sell
Strong Sell
Analyst Rating
12345
3.8
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Compare

EPS worse than industry
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.
CYTK
IMVT

FAQ

Q

How do I buy Cytokinetics (CYTK) stock?

A

You can purchase shares of Cytokinetics (NASDAQ: CYTK) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are Cytokinetics's (CYTK) competitors?

A

Other companies in Cytokinetics’s space includes: Immunovant (NASDAQ:IMVT), Legend Biotech (NASDAQ:LEGN), Sarepta Therapeutics (NASDAQ:SRPT), Exact Sciences (NASDAQ:EXAS) and Ionis Pharmaceuticals (NASDAQ:IONS).

Q

What is the target price for Cytokinetics (CYTK) stock?

A

The latest price target for Cytokinetics (NASDAQ: CYTK) was reported by HC Wainwright & Co. on Thursday, May 9, 2024. The analyst firm set a price target for 94.00 expecting CYTK to rise to within 12 months (a possible 49.40% upside). 36 analyst firms have reported ratings in the last year.

Q

Current Stock Price for Cytokinetics (CYTK)?

A

The stock price for Cytokinetics (NASDAQ: CYTK) is $62.92 last updated Today at May 10, 2024 at 2:47 PM EDT.

Q

Does Cytokinetics (CYTK) pay a dividend?

A

There are no upcoming dividends for Cytokinetics.

Q

When is Cytokinetics (NASDAQ:CYTK) reporting earnings?

A

Cytokinetics’s Q2 earnings are confirmed for Thursday, August 1, 2024.

Q

Is Cytokinetics (CYTK) going to split?

A

There is no upcoming split for Cytokinetics.

Q

What sector and industry does Cytokinetics (CYTK) operate in?

A

Cytokinetics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

People Also Watch